# Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

> **NCT00078455** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company**

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** ILX651

## Key facts

- **NCT ID:** NCT00078455
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** — (—)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078455, "Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00078455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*